Cibc World Market Inc. lifted its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 6,613.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 498,393 shares of the biotechnology company's stock after acquiring an additional 490,969 shares during the quarter. Cibc World Market Inc. owned approximately 0.34% of Biogen worth $112,577,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also modified their holdings of BIIB. BlackRock Inc. acquired a new position in shares of Biogen during the 2nd quarter worth $3,453,878,000. Orbimed Advisors LLC bought a new position in shares of Biogen during the 1st quarter valued at $11,293,000. Tidal Investments LLC lifted its stake in shares of Biogen by 9.0% in the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company's stock valued at $13,794,000 after purchasing an additional 5,256 shares during the last quarter. Saudi Central Bank boosted its holdings in Biogen by 89.7% in the second quarter. Saudi Central Bank now owns 10,273 shares of the biotechnology company's stock worth $2,220,000 after purchasing an additional 4,858 shares in the last quarter. Finally, Nippon Life Global Investors Americas Inc. bought a new stake in Biogen in the second quarter worth $29,648,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the company. Morgan Stanley raised their target price on Biogen from $231.00 to $238.00 and gave the company an "equal weight" rating in a report on Thursday, October 29th. UBS Group upped their price target on Biogen from $270.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, October 29th. Royal Bank Of Canada increased their price objective on Biogen from $256.00 to $272.00 and gave the company an "outperform" rating in a report on Thursday, October 29th. Mizuho raised their price objective on Biogen from $221.00 to $241.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. Finally, Canaccord Genuity Group boosted their target price on Biogen from $248.00 to $272.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Biogen presently has a consensus rating of "Moderate Buy" and an average price target of $254.41.
Get Our Latest Stock Report on Biogen
Top Biogen Stories
Here are a few of the latest stories about BIIB:
- Positive Sentiment: Five-year lecanemab (LEQEMBI) extension data showed sustained benefit in early Alzheimer’s disease. Compared with an external natural-history dataset, treatment was associated with a 36% lower relative risk of progression to the next disease stage; among patients with low tau, 62% showed improvement on a cognitive and daily-living measure. No new safety findings were reported, though the comparison was not against a concurrent placebo group throughout the five years. Read the lecanemab data announcement
- Positive Sentiment: Biogen’s Q3 growth portfolio revenue rose 49% year over year, while core pharmaceutical revenue totaled $2 billion. That growth may help offset pressure on older products and strengthen the company’s revenue outlook. Read the investor takeaways
- Positive Sentiment: Biogen entered a research collaboration with TRIMTECH to develop small-molecule protein degraders for neurodegenerative diseases, adding an exploratory pipeline opportunity. Read the collaboration announcement
Biogen Stock Performance
Shares of BIIB opened at $250.79 on Wednesday. The company has a market capitalization of $37.07 billion, a PE ratio of 107.18, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. Biogen Inc. has a one year low of $160.36 and a one year high of $261.00. The company's fifty day moving average price is $234.73 and its 200 day moving average price is $205.80.
Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.63. The company had revenue of $2.80 billion during the quarter, compared to analysts' expectations of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company earned $4.81 earnings per share. As a group, analysts expect that Biogen Inc. will post 12.46 earnings per share for the current year.
Biogen Profile
(
Free Report)
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.